X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55) 55
oncology (55) 55
female (52) 52
index medicus (52) 52
breast cancer (51) 51
breast neoplasms - drug therapy (35) 35
chemotherapy (34) 34
middle aged (34) 34
adult (32) 32
breast neoplasms - pathology (31) 31
aged (26) 26
disease-free survival (22) 22
cancer (20) 20
metastasis (20) 20
therapy (19) 19
treatment outcome (19) 19
tumors (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
cancer therapies (18) 18
survival (18) 18
care and treatment (14) 14
trastuzumab (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
drug therapy (12) 12
endocrine therapy (12) 12
erbb-2 protein (12) 12
patients (12) 12
analysis (11) 11
breast neoplasms - mortality (11) 11
efficacy (11) 11
medicine & public health (11) 11
paclitaxel (11) 11
research (11) 11
studies (11) 11
breast neoplasms - genetics (10) 10
chemotherapy, adjuvant (10) 10
docetaxel (10) 10
drug administration schedule (10) 10
estrogen (10) 10
metastases (10) 10
postmenopausal women (10) 10
prognosis (10) 10
tamoxifen (10) 10
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
clinical trials (9) 9
kaplan-meier estimate (9) 9
male (9) 9
time factors (9) 9
breast tumors (8) 8
combination (8) 8
dose-response relationship, drug (8) 8
follow-up studies (8) 8
hematology, oncology and palliative medicine (8) 8
women (8) 8
antibodies, monoclonal, humanized - administration & dosage (7) 7
antineoplastic agents, hormonal - therapeutic use (7) 7
breast neoplasms - surgery (7) 7
capecitabine (7) 7
cyclophosphamide (7) 7
genes (7) 7
her2 (7) 7
medicine (7) 7
medicine, general & internal (7) 7
mutation (7) 7
post-menopause (7) 7
proportional hazards models (7) 7
surgery (7) 7
survival analysis (7) 7
womens health (7) 7
abridged index medicus (6) 6
antibodies, monoclonal, humanized - adverse effects (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
aromatase inhibitors - adverse effects (6) 6
biomarkers (6) 6
breast (6) 6
breast neoplasms - metabolism (6) 6
epidermal growth factor (6) 6
fluorouracil - administration & dosage (6) 6
gene expression (6) 6
gene expression profiling (6) 6
infusions, intravenous (6) 6
maximum tolerated dose (6) 6
metastatic breast cancer (6) 6
multidisciplinary sciences (6) 6
patient outcomes (6) 6
proteomics (6) 6
science (6) 6
toxicity (6) 6
adjuvant chemotherapy (5) 5
androstadienes - administration & dosage (5) 5
animals (5) 5
aromatase (5) 5
aromatase inhibitors (5) 5
article (5) 5
biomarkers, tumor - analysis (5) 5
breast neoplasms - chemistry (5) 5
cancers and neoplasms (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Journal Article
by Colleoni, Marco and Luo, Weixiu and Karlsson, Per and Chirgwin, Jacquie and Aebi, Stefan and Jerusalem, Guy and Neven, Patrick and Hitre, Erika and Graas, Marie-Pascale and Simoncini, Edda and Kamby, Claus and Thompson, Alastair and Loibl, Sibylle and Gavilá, Joaquín and Kuroi, Katsumasa and Marth, Christian and Müller, Bettina and O'Reilly, Seamus and Di Lauro, Vincenzo and Gombos, Andrea and Ruhstaller, Thomas and Burstein, Harold and Ribi, Karin and Bernhard, Jürg and Viale, Giuseppe and Maibach, Rudolf and Rabaglio-Poretti, Manuela and Gelber, Richard D and Coates, Alan S and Di Leo, Angelo and Regan, Meredith M and Goldhirsch, Aron and Vandebroek, An and Berliere, Martine and Mitine, Carine and Vuylsteke, Peter and Borms, Marleen and D'Hondt, Randal and Glorieux, Philippe and Mebis, Jeroen and Verhoeven, Didier and Coibion, Michael and Forget, Frederic and Duck, Lionel and Wyendaele, Wim and Barbeaux, Annelore and Salmon, Jean-Paul and Berteloot, Patrick and Vermeij, Joanna and Richard, Vincent and Cinieri, Saverio and Gianni, Lorenzo and Clerico, Mario and Pinotti, Graziella and Bernardo, Antonio and Biganzoli, Leo and Gennari, Alessandra and Graiff, Claudio and Amadori, Dino and Passalacqua, Rodolfo and Forbes, John and Francis, Prudence and Foo, Serene and Boyle, Frances and Redfern, Andrew and van der Westhuizen, Andre and Lewis, Craig and Sharma, Ravi and Sharma, Sharad and Beale, Philip and Byard, Ian and Begbie, Stephen and Sardelic, Frank and Abdi, Ehtesham and Clark, David and Chindewere, Aaron and Della-Fiorentina, Stephen and Asghari, Ray and Islam, Mohammed and Na Teo, Lee and White, Shane and Gilbert, Linda and Gardner, Katherine and Uhlmann, Catarina and Rauch, Daniel and Mannhart, Meinrad and Buser, Katharina and Dedes, Konstantin and Mueller, Andreas and Rageth, Christoph and Von Orelli, Stephanie and Senn, Hans Joerg and Pagani, Olivia and Pedrazzini, Augusto and Rochlitz, Christoph and Bodmer, Alexandre and Anchisi, Sandro and Zaman, Khalil and von Moos, Roger and Betticher, Daniel and ... and SOLE Investigators and Institute of Clinical Sciences, Department of Oncology and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för kliniska vetenskaper, Avdelningen för onkologi
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 127 - 138
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Journal Article